🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

To Develop and Validate an Equation for Determination of Major Adverse Kidney Events in Patients With Decompensated Cirrhosis and Ascites.

Recruitingn/aAges 18 Years - 65 YearsAllInstitute of Liver and Biliary Sciences, India
NCT07794787 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Acute kidney injury (AKI) is the sudden loss of kidney function that occurs frequently in hospitalised patients with cirrhosis. * It develops in up to 53% and is independently associated with high short-term mortality. * A diagnosis of AKI (even stage 1 AKI) has been shown to be associated with an increased risk of long-term mortality at 30-day, 90-day and 1-year, compared to patients without AKI, even when there is recovery of AKI. * Risk factors with the strongest association for developing AKI include CKD, sepsis, spontaneous bacterial peritonitis (SBP), and presence of ascites. * AKI in cirrhosis is also associated with development of de-novo chronic kidney disease (CKD) , progressive loss of kidney function in patients with pre-existing CKD,recurrent AKI (i.e., AKI on top of CKD) and other organ failures * Kidney dysfunction in patients with cirrhosis is associated with a marked in

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Patients of cirrhosis with ascites with stable renal functions in last 7 days (variability in gfr \< 15 % and no AKI). Exclusion Criteria: 1. Patients with age \<18 or more than 65 years 2. Obstructive uropathy or intrinsic kidney disease 3. Patients with multiorgan failure or requiring mechanical ventilation 4. Patients who had previously undergone Liver or Kidney transplant 5. Patients with missing laboratory measurements within 24 hours of admission 6. HCC 7. Pregnant 8. Lack of baseline serum creatinine 9. Need of renal replacement therapy 10. HVOTO 11. Severe comorbid cardiopulmonary diseases or extrahepatic malignancy
💊

What it tests

  • Not listed
📍

Where

1 site
Institute of Liver & Biliary Sciences (ILBS)
New Delhi, India
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy